StreetInsider.com News Articles

Bionano OGM studies at ESHG 2026 rise 67% year over year

Thu, 18 Jun 2026 08:03:50 -0400

Bionano Genomics (Nasdaq: BNGO) said 35 studies featuring optical genome mapping (OGM) were presented at the 2026 European Society of Human Genetics (ESHG) conference, up from 21 at the 2025 event, a 67% year-over-year increase, according to a press release from the San Diego-based company.

Authors of the studies spanned 17 countries, compared with 12 countries at the prior year's conference, across five regions: Europe, North America, South America, Asia, and the Middle East. Europe contributed the most studies overall, while Brazil was the single largest national contributor.

Rare and constitutional genetic disorders represented approximately half of the studies. Other research areas

Bionano OGM studies at ESHG 2026 rise 67% year over year

Thu, 18 Jun 2026 08:03:50 -0400

Rare and constitutional genetic disorders represented approximately half of the studies. Other research areas

Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption

Thu, 18 Jun 2026 08:00:00 -0400

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics (ESHG) conference grew substantially compared to the conference in 2025, consistent with expanding global adoption of OGM.

Key highlights from studies of OGM presented at ESHG 2026:

35 studies featured OGM — a 67% increase over the 21 studies reported at ESHG 2025.
Authorship spanned 17 countries, up from 12 in 2025, across five global markets: Europe, North America, South America, Asia and the Middle East.
Rare and

Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption

Thu, 18 Jun 2026 08:00:00 -0400

Key highlights from studies of OGM presented at ESHG 2026:

35 studies featured OGM — a 67% increase over the 21 studies reported at ESHG 2025.
Authorship spanned 17 countries, up from 12 in 2025, across five global markets: Europe, North America, South America, Asia and the Middle East.
Rare and

Bionano reports studies show optical genome mapping detects genetic variants in reproductive health

Thu, 11 Jun 2026 08:04:10 -0400

Bionano Genomics (NASDAQ: BNGO) announced that 13 studies published in 2026 involving 730 samples demonstrated the utility of optical genome mapping (OGM) in detecting structural variants related to reproductive health and prenatal genetic disorders.

The studies, conducted by independent research groups across multiple countries, examined applications including male infertility, assisted reproduction, recurrent pregnancy loss, and prenatal diagnosis. Sample types included peripheral blood, prenatal specimens, and products of conception.

According to the company, key findings from nine studies showed OGM identified genetic causes in 25% of subjects with unexplained infertility among 220 individuals. The technology revised or corrected genetic findings in 58.3% of

Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders

Thu, 11 Jun 2026 08:00:00 -0400

Findings from 13 different studies analyzing 730 subjects to date in 2026 across multiple geographies underscore utility of OGM in key research areas including infertility, recurrent pregnancy loss, preimplantation genetics and prenatal genetic conditions

SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that to date in 2026, a total of 13 studies analyzing 730 samples were published with key findings that demonstrate the utility of optical genome mapping (OGM) for the detection and characterization of structural variants (SVs) in studies of reproductive health and prenatal genetic disorders. Reproductive disorders including infertility and recurrent

Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders

Thu, 11 Jun 2026 08:00:00 -0400

Form 8-K Bionano Genomics, Inc. For: Jun 02

Fri, 05 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26610862.html

Form 8-K Bionano Genomics, Inc. For: Jun 02

Fri, 05 Jun 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260605/26610862.html

Form 4 Bionano Genomics, Inc. For: Jun 03 Filed by: Dixon Jonathan V.

Wed, 03 Jun 2026 20:52:00 -0400

si-local-file:///var/storage/secattach/20260603/26601091.html

Form 4 Bionano Genomics, Inc. For: Jun 03 Filed by: Dixon Jonathan V.

Wed, 03 Jun 2026 20:52:00 -0400

si-local-file:///var/storage/secattach/20260603/26601091.html

Form 4 Bionano Genomics, Inc. For: Jun 03 Filed by: Chaubey Alka

Wed, 03 Jun 2026 20:51:00 -0400

si-local-file:///var/storage/secattach/20260603/26601088.html

Form 4 Bionano Genomics, Inc. For: Jun 03 Filed by: Chaubey Alka

Wed, 03 Jun 2026 20:51:00 -0400

si-local-file:///var/storage/secattach/20260603/26601088.html

Form 4 Bionano Genomics, Inc. For: Jun 03 Filed by: OLDAKOWSKI MARK

Wed, 03 Jun 2026 20:51:00 -0400

si-local-file:///var/storage/secattach/20260603/26601089.html

Form 4 Bionano Genomics, Inc. For: Jun 03 Filed by: OLDAKOWSKI MARK

Wed, 03 Jun 2026 20:51:00 -0400

si-local-file:///var/storage/secattach/20260603/26601089.html

Form 4 Bionano Genomics, Inc. For: Jun 03 Filed by: Adamchak Mark

Wed, 03 Jun 2026 20:50:00 -0400

si-local-file:///var/storage/secattach/20260603/26601086.html

Form 4 Bionano Genomics, Inc. For: Jun 03 Filed by: Adamchak Mark

Wed, 03 Jun 2026 20:50:00 -0400

si-local-file:///var/storage/secattach/20260603/26601086.html

Bionano retires $20 million convertible debt, eliminates secured obligations

Thu, 28 May 2026 08:09:20 -0400

Bionano Genomics Inc. (NASDAQ: BNGO) announced it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures worth $20 million in aggregate face value. The company used cash on hand to retire the debt instruments, which were originally issued in May 2024.

The retirement eliminates all of Bionano's secured debt obligations and releases liens on the company's assets. Associated restrictive covenants have been extinguished, according to the company's statement.

"Retiring this debt is a significant milestone for Bionano and a direct reflection of the progress we have made in strengthening and simplifying the business," said Al Luderer, chairman and interim chief

Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures

Thu, 28 May 2026 08:00:00 -0400

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the "Debentures"). The Company used cash on hand to retire the Debentures, which were originally issued in May 2024 in the aggregate face value of $20,000,000.

The retirement of the Debentures completes the debt restructuring the Company undertook in May 2024 and results in Bionano carrying no outstanding secured debt obligations. With the retirement, all liens on the Company's assets are released and the associated restrictive covenants are extinguished,

Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures

Thu, 28 May 2026 08:00:00 -0400

Form 8-K Bionano Genomics, Inc. For: May 28

Thu, 28 May 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260528/26561452.html

Form 8-K Bionano Genomics, Inc. For: May 28

Thu, 28 May 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260528/26561452.html

Bionano study finds genome mapping detects 97.8% of T-cell leukemia cases

Tue, 26 May 2026 08:05:47 -0400

Bionano Genomics Inc. (NASDAQ: BNGO) announced publication of a study in Modern Pathology showing its optical genome mapping technology detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia cases, compared to 55% detection by conventional cytogenetic analysis.

The study examined 91 T-ALL cases using three different analysis methods: optical genome mapping, conventional karyotyping and next-generation sequencing. Researchers from The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine conducted the analysis.

The optical genome mapping technology provided additional genomic insights beyond standard methods in approximately 70% of cases. The technology detected gene rearrangements in 80% of

Bionano study finds genome mapping detects 97.8% of T-cell leukemia cases

Tue, 26 May 2026 08:05:47 -0400

The optical genome mapping technology provided additional genomic insights beyond standard methods in approximately 70% of cases. The technology detected gene rearrangements in 80% of

Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia

Tue, 26 May 2026 08:00:00 -0400

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) detected genomic abnormalities in 97.8% of T-cell acute lymphoblastic leukemia (T-ALL) cases — nearly double the 55% detection rate achieved by conventional cytogenetic analysis. Conducted by researchers at The University of Texas MD Anderson Cancer Center and Johns Hopkins University School of Medicine and representing one of the most comprehensive genomic analyses of T-ALL to date, the study underscores OGM’s potential to transform how this aggressive blood cancer is